June 26 (Reuters) - Invivyd Inc IVVD.O:
INVIVYD ANNOUNCES POSITIVE FULL PHASE 1/2 CLINICAL DATA FOR VYD2311, A NEXT GENERATION COVID-19 MONOCLONAL ANTIBODY FOR POTENTIAL USE AS A NON-VACCINE PREVENTATIVE AND FOR TREATMENT OF ACTIVE INFECTION
INVIVYD INC - VYD2311 SHOWS ATTRACTIVE SAFETY PROFILE ACROSS ALL DOSING COHORTS
INVIVYD INC - TYPE C MEETING WITH FDA SCHEDULED FOR EARLY Q3
Source text: ID:nGNX8R7BBD
Further company coverage: IVVD.O
((Reuters.Briefs@thomsonreuters.com;))